|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Selling,
General and Administrative (SG&A) Expenses
SG&A expense was $292.7 million in 2008,
$339.3 million in 2007 and $360.3 million in 2006. The
decrease of 14% in total SG&A expense in 2008, compared to
2007, principally reflects reduced sales and marketing costs
resulting from the restructuring of our commercial
infrastructure related to the approval of a generic form of
Maxipime in June 2007 and the anticipated approval of a
generic form of Azactam, along with reduced amortization
expense following the impairment of our Maxipime and
Azactam intangible assets. The SG&A expense related
to the Tysabri ROW sales are reflected in the Tysabri
ROW revenue as previously described.
The decrease of 6% in total SG&A expense in 2007, compared
to 2006, reflected principally the restructuring of our
commercial infrastructure as described above and the decrease in
share-based compensation expense related to SG&A from
$28.8 million in 2006 to $23.9 million in 2007.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Selling,
General and Administrative (SG&A) Expenses
SG&A expense was $341.8 million in 2007,
$362.4 million in 2006 and $359.4 million in 2005.
Total SG&A expense for 2007 included $78.4 million
(2006: $75.0 million; 2005: $84.7 million) in relation
to Tysabri. The decrease of 6% in total SG&A expense
in 2007 compared to 2006 primarily reflects the restructuring of
our commercial infrastructure related to the approval of a
generic form of Maxipime in June 2007 and the anticipated
approval of a generic form of Azactam, along with reduced
amortization expense following the impairment of our Maxipime
and Azactam intangible asset, which resulted in the
reduction of related selling and administrative costs. In
addition, share-based compensation expense related to SG&A
decreased to $23.9 million in 2007, compared to
$28.8 million in 2006. The increase in SG&A expense
related to Tysabri reflects the relaunch of Tysabri
in the United States in 2006. The SG&A expense related
to the Tysabri ROW sales are reflected in the Tysabri
ROW revenue as previously described.
The increase of 1% in total SG&A expense in 2006 compared
to 2005 reflected the expensing of share-based compensation of
$28.8 million in 2006 (2005: $Nil), offset by decreased
expenses in relation to Tysabri and also due to ongoing
financial discipline. The decrease in SG&A expense related
to Tysabri in 2006 compared to 2005 reflected the impact
of the temporary suspension of Tysabri in 2005 and the
relaunch of Tysabri in the United States in 2006,
partially offset by the expensing of share-based compensation of
$2.5 million (2005: $Nil).
Table of Contents
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
